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Article Information  ABSTRACT 
Received: 12th October 2018   Floating drug delivery is considered as the most effective amongst the several approaches of 
gastro retentive drug delivery systems. The short gastric residence times (GRT) and 
unpredictable gastric emptying times (GET) are the two most important parameters that play a 
vital role in improving the bioavailability of drugs those are having an absorption window at the 
stomach. The floating drug delivery approach is a low-density system that may be effervescent or 
Non-Effervescent type with sufficient buoyancy to flow over the gastric contents and remain 
buoyant in the stomach without affecting the stomachic emptying rate for a prolonged duration. 
Floating dosage forms include tablets, granules, capsules, microspheres, microparticle, etc. are 
few formulations available commercially. A comprehensive summary of different floating drug 
delivery and its present status has been highlighted in this review. 
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INTRODUCTION 
The oral route drug administration gained its popularities due 
to some of the unique features includes the reasonable cost of 
therapy, ease of administration, better patient compliance and 
acceptability, good range of available dosage form [1,2]. 
Despite certain diversity, the oral route of drug delivery has 
several limitations to deliver the drug in the upper part of GIT 
[3]. It is reported the drug induces orally may take 1 to 2 hours 
to move away from the stomach region to intestine whereas, it 
spend 14-24 hours inside intestine [4,5]. As a result, drugs 
especially those are having absorption windows in the stomach 
face serious bioavailability issues due to short residence time 
[6-7].  
It is evident from the reported literature that growing interest 
has been observed in the development of oral Controlled 
release dosage forms that capable to deliver the drug at a 
predetermined rate for a prolonged period of time. Floating 
drug delivery systems (FDDS) is one, amongst the several 
approaches that are likely used in prolongation of the gastric 
residence times (GRT) [8,9].  
There are numerous drug substances available that may get 
benefit from prolonged GI passage times or stomach residence 
time and consequently, the bioavailability and the therapeutic 
efficacy may improve that ultimately leads to a reduction of 
dosage frequency and improve patient compliance. 
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Drugs that are absorbed from the stomach includeantacids, 
antibiotics albuterol, chlordiazepoxide, are rapidly absorbed 
from GIT [12-13]. Drugs having low bioavailability e.g.- 
ranitidine, misoprostol, and drugs which are poorly soluble in 
intestinal pH .e.g.- diazepam, dipyridamole is also reported to 
show good response as FDDS [14]. It releases at the site of 
absorption and thus enhanced bioavailability. 
 
Figure 1: Approaches for gastro retentive drug delivery 
system 
 
TYPES OF FDDS 
Based on the mechanism of buoyancy, FDDS can be divided 
into two distinct types: 
1. Effervescent system 2. Non-effervescent system  
1. Effervescent System: The effervescent system also known 
as gas generating system that fabricated using gas generating 
agents include carbonates (sodium bicarbonate), organic acids 
(citric acid, tartaric acid) that together will generate carbon 
dioxide gas [15-16]. The generation of carbon dioxide reduces 
the density of the dosage form that helps to float the system in 
the stomach thus increase GI retention time. This system is 
further classified into two types – Volatile liquid containing 
system and gas generating system. 
a. The volatile liquid containing system: This system may 
be composed of volatile liquids like ether, cyclopentane etc 
b. Gas generating system: This system mainly involves the 
use of agents which release carbon dioxide after a 
chemical reaction. Agents like sodium bicarbonate, citric 
acid, tartaric acid, chitosan, etc. are mainly used for this 
purpose. 
2. Non-Effervescent System: This system mainly composed 
of low density polymers that increase the effective surface 
area for the dosage form and allow the dosage form to float 
for an extended duration. Generally gel-forming or 
extremely swellable polysaccharide, sort hydrocolloids, 
matrix-forming materials such as polycarbonate, 
polyacrylate, polystyrene, and bio-adhesive materials such 
as chitosan and Carbopol may be used in this system [17-
18] 
 
Table 1: Advantages and disadvantages of Floating drug 
delivery system [13-16]
 
Advantages 
1. FDDS enhances the bioavailability of drugs those having 
an absorption window in the stomach. 
2. FDDS minimizes the adverse effect of drugs on the colon 
3. FDDS also reduces the counter activity of the body leading 
to higher drug efficacy. 
4. The FDDS is helpful for the drugs which are absorbed in 
the proximal part of the small intestine. 
5. FDDS is advantageous for locally acting drugs in the 
stomach. 
6. FDDS improves gastric residence time hence drug 
absorption is also improved. 
Disadvantages 
1. Sufficient stomach fluid is required for effective treatment. 
2. The drugs that undergoes high first-pass metabolism is not 
a suitable candidate for the purpose. 
3. Drugs that produce gastric irritation are not suitable  
4. Drugs having low aqueous solubility & stability problems 
in the GI tract are also not suitable candidates for FDDS 
5. The drug substances that are unstable in the acidic 
environment of the stomach are not suitable candidates.  
 
PHYSIOLOGY OF STOMACH 
The stomach is mainly divided into 3 regions: fundus, body, 
and antrum. The process of storing and digestion of food 
occurs within these regions. The gastric emptying occurs both 
during fasting state and feed state but the pattern of motility 
differ in both of these states [16,19]. The GI motility of the 
stomach consists of two modes, include inter-digestive motility 
and digestive motility. In a fasting state, a series of electrical 
events take place which cycle in the stomach and small 
intestine in every 2 to3 hours. This cycle is called an inter-
digestive myoelectric cycle (IMC) or migrating myoelectric 
cycle (MMC) [20]. Each cycle lasts for 90 to 120 min and 
consists of four phases as described by Wilson and Washington 
[21].  
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Fig 1: Structural configuration of stomach 
 
A full cycle begins in the lower esophageal sphincter and 
finished in the ileum. The phases of the cycle are as follows- 
a) Phase 1: In this phase, the gastric emptying rate is slow as 
the onset of MMC is delayed. This phase usually lasts for 
30 to 60 min. Contraction does not occur in this phase. It is 
also known as the basal phase.  
b) Phase 2: In this phase bile secretion and mucus discharge 
take place and intermediate contraction occurs. It lasts for 
20 to 40 min. It is also known as the pre-burst phase. The 
intensity and frequency increase gradually as the phase 
progresses.  
c) Phase 3: In this phase, regular and intense contraction takes 
place for a short time. It last usually for 10 to 20 min. This 
phase is also called a housekeeper wave as it tends to empty 
the fasting contents of the stomach. Large objectives remain 
in the stomach in the fed state but passed down to the small 
intestine during this phase.  
d) Phase 4: This is the intermediate state between phase 3 and 
1. It lasts from 0 to 5 min 
 
FACTORS AFFECTING GASTRIC RESIDENCE TIME OF 
FDDS 
Factors that affect gastric emptying time are as follows- 
1. Effects of dosage form size and shape: Small size solid 
dosage form is generally expelled from the stomach during 
the digestive phase while the large size follows 
housekeeping wave phase. It is found that floating units 
have large GRT than the non-floating unit. The tetrahedron 
and ring-shaped matters have a better GRT as compared 
with other shapes [22]. 
2. Gender, posture and age: Women are having lower gastric 
emptying rates than men. In the case of an elderly person, 
gastric emptying time is slowed down especially in the case 
of a person above 70 years [22]. 
3. Effect of food and specific gravity: Low-density dosage 
form shows a higher duration of floating and comparatively 
slow gastric emptying rate. Several reported literature states 
that the intake of food is the main determinant in gastric 
emptying rate [23] 
4. Nature of meal and frequency of food: The rate of the 
gastric emptying time mainly depends on the volume, 
viscosity and calorie content of meals. Feeding of 
indigestible material or fatty acid can change the motility 
pattern of the stomach. It can increase the gastric emptying 
rate and prolong the release of the drug. A protein-rich diet 
can increase GRT by 4-10 hours [23] 
5. Diseases State: Diseases like Diabetes, Chron’s disease, 
etc. can alter the gastric emptying time. Depression slows 
the gastric emptying time while stress increases the rate 
6. Effect of drugs: Drugs like atropine, glycopyrrolate, 
metoclopramide, domperidone, etc increases the gastric 
emptying time while anti-cholinesterase drug-like 
neostigmine decreases the gastric emptying rate. 
7. State of the drug: A demonstration using a radio labeled 
technique shows that the rate of gastric emptying time 
differs between liquid, digestible solid & indigestible solid. 
8. Formulation parameters: Multi-particulate formulations 
show a better gastric emptying pattern than the single unit 
formulations. 
 
COMPONENTS OF FDDS 
Following components are used in the formulation of FDDS- 
Hydrocolloids- Hydrocolloids are synthetic, anionic or non-
ionic slightly modified cellulose derivatives e.g. - acacia, 
pectin, agar, gelatin, bentonite etc [24] 
Polymers-  Polymers like HPMC K4M, HPMC K15M, HPMC 
K100M, polyethylene glycol, polycarbonate, sodium alginate, 
PVA, PVP, eudragit, carbopol, methyl methacrylate, acrylic 
polymers are mostly used for the development of floating drug 
delivery [25
-
26] 
Effervescent agent- Sodium bicarbonate, citric acid, tartaric 
acid, nitroglycerin, Di-sodium glycine carbonate etc. are used 
as an effervescent agent in the preparation of effervescent 
based floating formulation [27] 
Inert fatty materials- Fatty materials have a specific gravity 
less than one which decreases the hydrophilic property and 
hence increased buoyancy. E.g. Beeswax, fatty acid, long-chain 
alcohol, mineral oil [27] 
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Release rate modifier - The release rate of the formulation can 
be modified by using excipients like lactose, mannitol [18,27]. 
Release rate retardants – They decrease the solubility hence 
retard the release rate of medicaments. E.g.- dicalcium 
phosphate, talc, Mg stearate[18]. 
Buoyancy increasing agent- Materials like ethyl cellulose 
which has a low bulk density less than one can be used for 
increasing the buoyancy of the formulation. It may be present 
with 80% of the weight[18]. 
Low-density material – They are used if necessary to decrease 
the weight of the formulation for them to float e.g.- 
Polypropylene foam powder. 
Miscellaneous – Adjuvant like preservatives, stabilizers, 
lubricants, binders, etc can be used in the formulation as per 
requirements. 
 
CHARACTERIZATION 
Most of the reported floating formulation is either a single unit 
type (Tablet) or multi-unit type (microspheres/ microcapsule/ 
microbeads) of preparation. Therefore, the characterization of 
both the type are discussed chronologically as follows  
 
Pre-compression study (single unit dosage form): 
Compatibility studies between drugs and excipients: The 
physical compatibility study of drug and excipients are carried 
out to determine the possible physiochemical interactions. The 
study can be performed using FTIR, DSC or X-Ray diffraction 
technique [29]. 
Angle of Repose: In this study accurately weighed mixture of 
powder/granules/microparticles are placed in a funnel. The 
funnel may be adjusted in such a way that the tip of the funnel 
just touches the apex of the heap of blends. The blends are 
allowed to flow through the funnel freely on a horizontal 
surface. The diameter of the speeded mass (powder/granules/ 
microparticles) will be measure, and the angle of repose can be 
determined by using the following equation [30]. 
Tan θ=  
 
 
 
Where,  θ = angle of repose, h = height in cm, r =radius in cm. 
Bulk density 
Apparent bulk density was measured by pouring the pre-
weighted blend of powder into a graduated cylinder. The bulk 
volume of the blend was determined, and then the bulk density 
may be calculated by using the formula. 
Bulk Density = 
                  
                     
 
Tapped density 
The measuring cylinder containing a known mass of blend is 
tapped for a fixed duration of time and from a specific height as 
per standard protocol.The initial volume occupied in the 
cylinder is measured and the same processes are applied after 
tapping. The tapped density may be calculated by using the 
following formula  
Tapped Density = 
              
                               
 
Carr’s index (I):The compressibility index can be determined 
from the value of bulk and tapped densities[32].The percentage 
compressibility of the bulk drug can be determined using the 
following formula. It is expressed in percentage - 
I = 
     
  
 ×100 
Where Dt is the tapped density of the powder and Db is the 
bulk density of the powder. 
Hausner ratio: Hausner ratio can be calculated by the formula: 
Hausner ratio = Tapped Density/ Bulk Density 
 
Post-compression parameters: 
The single unit floating dosage form(tablet) can be subjected 
toquality control tests like weight variation, hardness, 
thickness, friability, and content uniformity. 
Determination of hardness:  
The hardness of the tablet is determined by using Monsanto or 
Pfizer Hardness tester. The tablets are placed between two 
loads, adjusted with a spindle, and the pressure required to 
break the tablets are measure. The average value of 3 tablets 
may be noted. 
Disintegration Time:In-Vitro disintegration time can be 
determined by using the disintegration test apparatus. For this, 
the tablet is placed in each of the six tubes of the apparatus and 
one disc is added to each tube. The time taken for the complete 
disintegration of the tablet is measured. 
Determination of friability 
Roche friabilator may be used to perform the study. Previously 
weighted 20 matrix tablets may be placed in the friabilator and 
rotation speed and duration of rotation may be set as per the 
standard protocol. After completion of the rotation, tablets are 
taken out from the machine and reweighted, the difference is 
noted as per the following formula 
F = 100 (1-w0 /w) 
Determination of weight variation 
Around 20 tablets were selected at random and weight 
accurately. Now, the average weight of the tablets may be 
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calculated. Then the deviation of individual weight from the 
total weight will be calculated. The obtained result will be 
compared with the given standard limits as per IP. 
Determination of thickness of tablets 
The thickness of tablets can be determined using slide calipers. 
The average thickness of five individual tablets may be 
reported as the thickness of the prepared tablet. 
Determination of drug content in tablets 
Randomly3 tablets from each batch are selected and transfer to 
a 100 ml volumetric flask contain suitable medium. Store the 
content for 48 hours then took 1ml from each of the volumetric 
flasks and transfer to the test tube. The collected samples are 
analyzed after suitable dilution using a UV spectrophotometer 
at a suitable wavelength. The linearity equation obtained from 
the calibration curve is used for the estimation of drug content 
[34
-
35].  
Tablet Dimensions: Thickness and diameter of tablets can be 
measured using a vernier caliper. Three tablets of each 
formulation are picked randomly and the dimension is 
determined. It is expressed in mm[35]. 
Buoyancy studies: In this study, the onset time of floating and 
duration of floating are measured. Randomly selected tablets 
are placed in a 250 ml beaker, containing 200 ml of 0.1 N HCl. 
The time required for the tablet to rise at the surface and the 
entire duration of time of tablet remain floated is 
determined[36]. 
Swelling study: The swelling index can be determined by 
placing the tablets separately in a glass beaker containing pH 
1.2 HCl buffer and incubated at regular 1-hr time intervals until 
24 hrs. The floating tablets are removed from beaker, and the 
excess surface liquid is removed carefully using the % swelling 
index (SI) and is calculated using the following formula[36-
37]: 
Swelling Index (SI %) =
   –   
  
× 100 
In Vitro Dissolution Studies: The in vitro dissolution study 
may be performed by using a United States Pharmacopeia 
(USP) type II (paddle) apparatus at a rotational speed of 100 
rpm. The dissolution test is performed using 900 ml of 0.1N 
HCl at 37
o
C ± 0.5
o
C. A sample (10 ml) of the solution is 
withdrawn from the dissolution apparatus at predetermined 
time intervals for 24 hrs and the samples were replaced with 
pre-warmed fresh dissolution media. The samples are filtered 
through a Whatman filter paper and diluted to a suitable 
concentration with 0.1 N HCl as a blank. The absorbance of the 
solution is measured at 276 nm using a UV spectrophotometer 
[6,38]. 
 
Evaluation of multi-unit type floating microspheres:  
The above-mentioned studies that refer for single unit dosage 
form like compatibility studies, buoyancy studies, 
micromeritics properties like angle of repose, bulk density, tap 
density, carr’s index, Hausner ratio are also applicable for 
multiunit floating formulations. Other important evaluations for 
multiunit floating dosage form are mentioned as follows    
Percentage yield (%): The percentage yield of floating 
microspheres can be measure by dividing the actual weight of 
the product by the total amount of all non-volatile components. 
Following formula may be used tocalculate  
% yield =
                             
                          
×100 
Determination of Particle size: Particle size and shape of the 
microspheres are determined by the microscopic method. 
Microspheres to be examined are placed under a microscope 
and the size of individual particles is determined using 
eyepiece micrometer and stage micrometer. Average particle 
size is measured and reported 
Drug entrapment efficiency: Drug entrapment efficiency of 
microspheres may be performed by accurately weighing a 
certain amount of microspheres and crushing them properly 
using mortar and pestle. Then the crushed matter shall be 
suspended in the predetermined quantity of acid buffer and 
kept aside for 24 hours. After that, the content subjected to 
filtration and the filtrate is analyzed spectrophotometrically at a 
suitable wavelength. The percent of drug entrapped shall be 
calculated as follows: 
Entrapment efficiency =
                       
                        
×100 
Surface morphology: The surface morphology was measured 
by using a scanning electron microscope (SEM). 
In-vitro drug release study: 
The in-vitro drug release may be carried out by using the 
dissolution test apparatus. Either a single tablet or floating 
microspheres are placed inside a dissolution apparatus. The 
study shall be carried out under a set of standard conditions. 
Throughout the study, the sink condition needs to be 
maintained and around 5 ml sample required to be transferred 
after a fixed time interval. The collected samples are analyzed 
under a UV spectrophotometer after suitable dilution. The 
amount of drug release may be calculated based on the 
obtained data [42]. 
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FUTURE PERSPECTIVE OF FDDS: 
Floating drug delivery is a potential approach and became a 
vital aspect of research for forthcoming era. Drugs that are 
having poor bioavailability owing to their restricted absorption 
in the upper gastrointestinal tract are effectively delivered 
through the floating delivery approach. However, several issues 
associated with the rational development of FDDS with the 
fasted and feed states are still under consideration [43]. The 
FDDS reduces fluctuations in the plasma level of drug results 
from delayed gastric emptying. The floating concept can also 
be utilized in the development of various anti-reflux 
formulations and these may play a potential role to treat 
Parkinson's disease.  
MARKETED FORMULATIONS OF FDDS 
Table 2: Commercially available floating drug delivery system 
Brand name Delivery system Drug Company 
Valrelease® Floating capsule   Diazepam Hoffmann-LaRoche 
Madopar® HBS (Prolopa® HBS) Floating, CR capsule Benserazide and L-Dopa Roche Products, USA 
Liquid Gaviscon® 
Effervescent Floating liquid 
alginate preparations 
Al hydroxide, Mg 
Carbonate   
GlaxoSmithKline, India 
CifranOD ® Gas-generating floating form Ciprofloxacin Ranbaxy, India 
Conviron®  The colloidal gel-forming FDDS Ferrous sulfate Ranbaxy, India 
Topalkan®   Floating liquid alginate preparation  Al – Mg antacid Pierre Fabre Drug, France 
Cytotech®   Bilayer floating capsule    Misoprostol Pharmacia, USA 
Table 3: List of Patents on Floating Drug Delivery System 
Title Patent Number Date Inventors Ref  
Gastric floating system WO02/102415A1 27 Dec 2002 Avachat MK., Dhamne AG. [44] 
Floating drug delivery composition WO01/58424A1 
16 Aug 
2001 
Watts PJ, Smith A, Bond JR and 
Lafferty WCI 
[45] 
Gastro retentive drug delivery system 
comprising an extruded hydratable polymer 
WO03/105812A1 24 Dec 2003 Hassan M [46] 
Gastro-retentive drug delivery system WO2014/014348A1 23 Jan 2014 
Meijerink HJC, Changoer L, Blom W, 
Visser MR, Frijlink HW, Eissens AC 
[47] 
Gastroretentive drug formulation & delivery 
systems and their method of preparation 
using functionalized calcium carbonate 
WO2014/057026A1 17 Apr 2014 
Gerard DE., Schoelkopf J, Gane PA.C, 
Eberle VA, Alles R, Puchkov M and 
Huwyler J 
[48] 
 
CONCLUSION 
Floating drug delivery system (FDDS) is a popular concept 
comes under gastro retentive drug delivery that effectively 
delivers the drug in the upper part of GIT. Drug molecules that 
are having an abortion window in the stomach can be safely 
delivered through this route. This drug delivery approach has 
gained considerable popularity as per patient acceptability and 
compliance is a concern.  
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